Tegaserod (maleate)

CAT:
804-HY-14153A-01
Size:
5 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Tegaserod (maleate) - image 1

Tegaserod (maleate)

  • UNSPSC Description:

    Tegaserod maleate (SDZ-HTF-919) is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod maleate has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod maleate causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod maleate has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research[1][2][3].
  • Target Antigen:

    5-HT Receptor; Apoptosis
  • Type:

    Reference compound
  • Related Pathways:

    Apoptosis;GPCR/G Protein;Neuronal Signaling
  • Applications:

    Neuroscience-Neuromodulation
  • Field of Research:

    Metabolic Disease; Neurological Disease; Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/Tegaserod-maleate.html
  • Solubility:

    DMSO : ≥ 35 mg/mL|H2O : < 0.1 mg/mL
  • Smiles:

    O=C(O)/C=C\C(O)=O.COC1=CC=C(NC=C2/C=N/NC(NCCCCC)=N)C2=C1
  • Molecular Weight:

    417.46
  • References & Citations:

    [1]M D Crowell, et al. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol Motil. 2005 Oct;17(5):738-43.|[2]D T Beattie, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60.|[3]Wei Liu, et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020 Feb 21;39(1):38.
  • Shipping Conditions:

    Room Temperature
  • Clinical Information:

    Launched
  • CAS Number:

    189188-57-6